Telix doses first patient in phase 3 brain cancer therapy trial

April 14, 2026 7:05 PM

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) announced that the first patient received TLX101-Tx treatment in its IPAX BrIGHT phase ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found